Predicine

10/17/2025

See New Groundbreaking Predicine Data at ESMO 2025 - Booth #2035

Predicine is proud to present 3 ctDNA studies that highlight our cutting-edge innovations in liquid biopsy. The forthcoming data represents significant potential for the practical application of Predicine’s technology including analysis of a broad range of liquid samples (urine, CSF, blood), utility of methylation detection in bispecific monoclonal antibody drug development, and organ sparing approaches for bladder cancer

Visit Predicine Booth #2035 to explore our end-to-end support for drug development and global clinical trials - from exploratory biomarkers to pivotal studies - across the US, EU, China, and beyond:

• Methylation-based detection of neuronendocrine subtyping in prostate cancer

• Explore genomics, epigenomics, and transcriptomics solutions for RAS, MTAP, PD1/VEGF, and ADC development

• Longitudinal ctDNA dynamics for efficacy prediction and monitoring

• Personalized, tumor-agnostic MRD with ultra-sensitive ctDNA profiling

• Centralized testing and decentralized kitted solutions to power global trials and CDx development

📅 Schedule a meeting with our team (in-person or virtual): MeetingESMO2025Booth2035@predicine.com?ismsaljsauthenabled=true" rel="ugc" target="_blank">https://outlook.office.com/book/MeetingESMO2025Booth2035@predicine.com?ismsaljsauthenabled=true

10/13/2025

Join us at the Predicine Liquid Biopsy Summit 2025 – Shanghai, part of Predicine’s Global 10th Anniversary Celebration Series, commemorating a decade of innovation in liquid biopsy and precision medicine.

• Date: October 25, 2025 (Saturday)

• Time: 9:00 AM - 3:00 PM (GMT +8)

• Venue: JW Marriott Hotel Shanghai, Tomorrow Square, Shanghai, China

Join peers from industry, academia, and clinical practice to explore the latest advances in liquid biopsy and precision oncology - and celebrate a decade of innovation and quality at Predicine.

Program highlights:

• Targeted Therapy: Liquid Biopsy for Drug Development - RAS & Beyond

• ADCs & Immunotherapy: Liquid Biopsy for Drug Development - PD1/VEGF & Beyond

• From China to the World: Biomarker-Enabled Acceleration of Global Clinical Trial

RSVP HERE: https://www.eventbrite.com/e/predicine-liquid-biopsy-summit-shanghai-tickets-1805698315269?aff=oddtdtcreator

A confirmation email will be sent based on first come first serve basis due to limited space.

We look forward to welcoming you to the event.

09/19/2025

Meet Predicine at JCA 2025 — ultra-sensitive liquid biopsy solutions for RAS, MTAP, PD‑1/VEGF, and ADC

High-sensitivity assays for screening, monitoring, MRD, and mechanism insights — booth # J-08

At JCA 2025, Predicine will share how our globally harmonized, ultra-sensitive blood- and urine-based liquid biopsy assays support RAS, MTAP, PD‑1/VEGF, and ADC programs by enabling:

• Patient screening and enrollment

• Treatment monitoring and resistance tracking

MRD assessment to inform endpoints and follow-up

• Mechanism-of-action and resistance investigations

MRD spotlight

• Blood-informed personalized MRD: ultra-deep ctDNA to define and longitudinally track patient-specific variants from baseline blood (with optional urine/tissue).

• Tumor-agnostic methylation MRD: targeted methylation signatures to detect residual disease without a tissue prerequisite; complements genomic MRD.

Poster at JCA 2025

• P‑1185: Liquid Biopsy Reveals Distinct Genomic Profiles of NSCLC in U.S. and Chinese Patient Cohorts

• Why it matters: regional genomic differences that can inform trial design, patient selection, and global strategies

Meet us on-site

• Booth J‑08

• Schedule a 1:1 with our team: MeetingJCA2025@predicine.com/?ismsaljsauthenabled=true" rel="ugc" target="_blank">https://outlook.office.com/book/MeetingJCA2025@predicine.com/?ismsaljsauthenabled=true

09/17/2025

Join Predicine at the World CB & CDx 2025 Summit at booth #42

Multi-omic liquid biopsy for CDx development and commercialization

At the World CB & CDx 2025 Summit, Predicine is showcasing how its’ comprehensive & ultra-sensitive liquid biopsy solutions accelerate biomarker-driven drug development and CDx launch across oncology.

What’s new:

• PredicineCARE for CDx commercialization with FDA Breakthrough, NY State permit, to PMA underway

• Genomic profiling using blood and urine to enable global clinical trials and CDx development

• Epigenomic methylation profiling for earlier readouts of therapy response and resistance

• RNA profiling to advance next-generation drug development through transcriptomic insights

Predicine’s platform is designed to support biomarker-driven drug development, from exploratory endpoints to pivotal studies.

📍 Join us at World CB & CDx 2025 Summit to explore collaborations that accelerate your biomarker programs.

📅 Schedule a meeting with our experts at booth #42 to learn how our liquid biopsy assays can enable your next trial.
MeetingWorldCBCDx2025@predicine.com/?ismsaljsauthenabled=true" rel="ugc" target="_blank">https://outlook.office.com/book/MeetingWorldCBCDx2025@predicine.com/?ismsaljsauthenabled=true

09/14/2025

Visit Predicine at Booth #6 — Multi-omic liquid biopsy for RAS drug development

Don’t miss our Sept 17th presentation addressing ultra-deep genomic sequencing, methylation, and cfRNA profiling for RAS-targeted drug development.

At the 7th RAS-Targeted Drug Development Summit, Predicine will share its integrated, multi-omic profiling data in liquid biopsy to enable faster, data-driven decisions in RAS-targeted clinical development.

Presentation

• Wednesday, September 17, 2025 | 1:50 PM ET

• Integrated Liquid Biopsy Profiling to Accelerate RAS Clinical Drug Development

What we’ll cover

• Genomic ultra-deep profiling using a blood-informed minimal residual disease (MRD) approach to support RAS-targeted clinical trials and enable data-driven go/no-go decision-making

• Epigenomic methylation profiling for enhanced detection of therapy response dynamics and resistance mechanisms

• Tissue and blood-based RNA profiling to advance next-generation RAS drug development through transcriptomic insights


Meet us on-site

• Booth #6

• Schedule a 1:1 with our team: Meeting7thRASTargetedDrugDevelopmentSummit@predicine.com?ismsaljsauthenabled=true" rel="ugc" target="_blank">https://outlook.office.com/book/Meeting7thRASTargetedDrugDevelopmentSummit@predicine.com?ismsaljsauthenabled=true

09/03/2025

Join Predicine at WCLC 2025 at booth #105!

📑 Featured Poster: Longitudinal ctDNA Profiling in HER2-Altered NSCLC Treated With HER2 ADC: Preliminary Results From the RESOLUTION Trial

This study demonstrates how ctDNA-guided monitoring can enable early detection of disease progression and real-time insights into treatment response in HER2+ NSCLC.

Learn more here: https://cattendee.abstractsonline.com/meeting/21151/Session/163

📍 At WCLC 2025, Predicine is showcasing how its’ comprehensive & ultra-sensitive liquid biopsy solutions are uniquely positioned to address emerging priorities in the lung cancer field such as:

• Patient enrollment – recruiting additional patients for KRAS, MTAP, MET, EGFR, HER2, ALK, ROS1 using an ultra-sensitive blood assay at the MRD level

• MRD Detection & Longitudinal Monitoring – blood-informed MRD approach, enabling earlier and actionable insights into recurrence and therapy response with high sensitivity for targeted therapy and PD1/VEGF

• Resistance Mechanisms – tracking biomarkers at an unprecedented MRD level in blood to guide next-line therapies

• Broad Assay Coverage – integrating ctDNA/cfRNA, and genomics, epigenomics, and transcriptomics to capture tumor heterogeneity and novel targets

• Global Scalability – seamless support for pharma clinical trials with fast turnaround, reproducibility, and harmonized testing solutions including US, EU, China, JP, and LATAM

🔗 Schedule a meeting with our team: https://lnkd.in/grdVE6B8

09/02/2025

Today we’re proud to share that Predicine has officially submitted the first module of its PMA application to the FDA for PredicineCARE™, a urine cfDNA NGS assay, as a companion diagnostic (CDx) for bladder cancer. It’s inspiring to see our collective efforts driving meaningful progress in cancer diagnostics and patient care.

This foundational submission includes comprehensive documentation of the Predicine FDA-grade manufacturing and quality systems, paving the way for future CDx indications across our liquid biopsy and tissue-based platforms.

Learn more here: https://www.globenewswire.com/news-release/2025/09/02/3142717/0/en/Predicine-Submits-First-Module-of-PMA-Application-to-FDA-for-PredicineCARE-as-a-Companion-Diagnostic-Assay-in-Bladder-Cancer.html

HAYWARD, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, today announced the submission of the first...